Filing Flows › Conmed (CNMD) › Q3 2026
Conmed (CNMD) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 28, 2026
Conmed (CNMD) reported revenue of $336M for the third quarter 2026 (Q3 2026), -0.7% from a year earlier and -2% from the quarter before. Operating margin was 11.1%, net earnings $19.8M (5.9% of revenue).
Conmed, Q3 2026: revenue $336M (-0.7% year over year), operating margin 11.1%, net earnings $19.8M, operating cash flow $49.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $336M | -2% | -0.7% |
| Gross profit | $189M | -4% | +14% |
| Operating profit | $37.1M | +2% | +213% |
| Net earnings | $19.8M | -14% | +592% |
| Operating cash flow | $49.4M | +33% | -8% |
| Free cash flow | $46.7M | +37% | -4% |
What changed
Revenue was $335.6M in Q3 2026, down 1% year over year and down 2% from the previous quarter. General Surgery was the largest line at 56% of revenue. General Surgery lost $13.0M year over year (down 7%), 549% of the total change.
Gross margin was 56.4%, up 7.2 points from Q3 2025. Operating profit was $37.1M, a 11.1% margin (up 7.6 points year over year). Operating expenses fell 1% while revenue fell 1%. The fastest-growing cost line was Research & development (+12%). Net earnings were $19.8M, up 592% year over year. The effective tax rate was 23.9%.
Operating cash flow was $49.4M (down 8% year over year), 250% of net earnings. Non-cash charges added back $12.8M of depreciation and amortization and $5.9M of share-based compensation. Working capital and other items added $10.9M. Capital expenditures of $2.7M left free cash flow of $46.7M.
Questions
What was Conmed's revenue in the third quarter 2026?
Conmed (CNMD) reported revenue of $336M for the third quarter 2026 (Q3 2026), -0.7% from a year earlier and -2% from the quarter before.
Was Conmed profitable in the third quarter 2026?
Operating profit was $37.1M (11.1% of revenue) and net earnings $19.8M.
Source: Conmed 10-Q on SEC EDGAR.